NCT02915016: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 3 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02915016 |
|---|---|
| Title | A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 7, 2016 |
| Completion date | Aug. 7, 2019 |
| Required reporting date | Aug. 6, 2020, midnight |
| Actual reporting date | Aug. 10, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 3 |